抑制肿瘤坏死因子-α (iTNF-α) 的单克隆抗体彻底改变了炎症性肠病的治疗方案，但其主要缺点是需要肠胃外给药途径。另一种方法是通过创新配方将这些分子递送到参与炎症过程的区域，从而促进它们在受影响组织中的定位，同时减少所需的给药次数。本综述描述了使用含有 iTNF-α 的基于脂质和聚合物的系统所带来的优势，重点关注其理化和技术特性，并讨论了使用结肠炎啮齿动物模型在体内获得的临床前结果。版权所有 © 2024 ）。由爱思唯尔有限公司出版。保留所有权利。

Monoclonal antibodies inhibiting tumor necrosis factor-alpha (iTNF-α) have revolutionized the therapeutic regimen of inflammatory bowel disease, but their main drawback is the parenteral route of administration they require. An alternative approach lies in the delivery of these molecules to the area involved in the inflammatory process by means of innovative formulations able to promote their localization in affected tissues while also decreasing the number of administrations required. This review describes the advantages deriving from the use of lipid- and polymer-based systems containing iTNF-α, focusing on their physicochemical and technological properties and discussing the preclinical results obtained in vivo using rodent models of colitis.Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.